Comparative Pharmacology
Head-to-head clinical analysis: CORTISONE ACETATE versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTISONE ACETATE versus KENALOG IN ORABASE.
CORTISONE ACETATE vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderateCortisone acetate + Levofloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life approximately 2-5 hours following mucosal application.
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid
Cortisone acetate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin."